Noom GLP-1 Program: An Independent Editorial Review

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This piece lives in the PlexusDx Education Hub, our library on GLP-1 therapies and the genetics behind metabolic decisions. Browse the Peptides & GLP-1 Education Hub

Read this as an independent editorial review. PlexusDx has no commercial relationship with Noom or its parent company, and no affiliate links or compensation are involved.

People searching for Noom's GLP-1 offering usually want to know how the medication side of the app actually functions. This review lays out Noom's GLP-1 structure — evaluation, prescription, and dispensing — as balanced editorial context rather than a recommendation, current as of April 2026.

What the Noom GLP-1 offering is

Noom, Inc. runs an app-based subscription with a medication add-on. In this model a member typically gets a virtual clinical evaluation from a licensed provider, a prescription sent either to a retail pharmacy for an FDA-approved brand or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide, and ongoing follow-up. For the current program and pricing, Noom's official website is the source of record.

Step by step through the program

GLP-1 telehealth programs tend to share a spine. First, an intake captures weight, medical history, and current medications. Next, a licensed clinician reviews eligibility and, where appropriate, issues a prescription. That order is then filled by a retail or licensed compounding pharmacy. Finally, follow-up visits guide dose titration and side-effect management. The differences between services show up in provider type, pharmacy partner, and how the subscription bundles medication with coaching.

What the GLP-1 add-on costs

Noom lists its own pricing, and a member's total shifts with the compound prescribed, the tier chosen, and whether a branded or compounded product is dispensed. Across the telehealth GLP-1 market as of April 2026, monthly spend generally sits between roughly $200 and $700 or more, with wide variation. Because pricing changes often, verify current numbers at Noom's official website before signing up.

The evidence behind GLP-1 medications

The pharmacology of any GLP-1 program comes from the drug class itself: GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide). Anchoring trials include STEP (semaglutide for weight management, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Trial populations and endpoints differ, and results vary from person to person.

The genetic variable Noom doesn't measure

An app and a prescription don't reach the genetic layer shaping your GLP-1 biology. Variants in FTO (fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene every compound targets), MC4R (a satiety-linked melanocortin receptor), and TCF7L2 (a transcription factor tied to glucose homeostasis) map the metabolic terrain any compound must operate across. Pathway-level by nature, they don't predict response to a given medication — they describe the biology a clinician is prescribing into.

The PlexusDx alternative

PlexusDx provides semaglutide and tirzepatide through its Weight Management Protocols — offered as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What comes first is the genetic step: the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R, and TCF7L2, so the conversation with your provider starts from your own baseline rather than a generic protocol.

Not affiliated: PlexusDx has no commercial relationship with Noom or any company reviewed here.

More from the Hub: what GLP-1 is, how GLP-1 receptor agonists work, the GLP-1 drug class, and the GLP-1 hormone.

Editorial note: this article is educational. PlexusDx is independent of Noom and supplies semaglutide and tirzepatide through its own Weight Management Protocols; this review compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test reflects how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the models: view the Weight Management Protocols, or start with your biology and take the Precision Peptide Genetic Test. Browse the Peptides & GLP-1 Education Hub

Frequently Asked Questions

Does Noom actually prescribe GLP-1 medication?

Noom offers GLP-1 access through a medication add-on layered on its app subscription, with prescriptions issued by licensed clinicians when eligibility is met. As with any telehealth service, the details of provider oversight and pharmacy partners are published on Noom's own site, which you should review before enrolling.

What GLP-1 options move through a program like Noom?

Programs in this model route prescriptions to a retail pharmacy for FDA-approved brand products or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Which option applies depends on eligibility and the program's pharmacy partners. Confirm specifics on Noom's website rather than assuming a particular compound.

Where does the Precision Peptide Genetic Test fit alongside a GLP-1 program?

It sits upstream. The test does not predict response to any compound or program; it reads pathway-level variants such as FTO and MC4R, and TCF7L2 that describe your baseline GLP-1 biology, adding context that a subscription app and prescription do not provide on their own.

How does PlexusDx differ from a GLP-1 subscription app?

PlexusDx delivers semaglutide and tirzepatide through its Weight Management Protocols and pairs them with the Precision Peptide Genetic Test for upstream pathway insight. A subscription app like Noom bundles coaching with a prescription but does not layer genetic pathway context alongside the medication.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.